SGMO vs. LXRX, MYGN, EBS, RIGL, XOMA, VSTM, VNDA, CBIO, CDXS, and AGEN
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Lexicon Pharmaceuticals (LXRX), Myriad Genetics (MYGN), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Crescent Biopharma (CBIO), Codexis (CDXS), and Agenus (AGEN). These companies are all part of the "biotechnology" industry.
Sangamo Therapeutics vs. Its Competitors
Lexicon Pharmaceuticals (NASDAQ:LXRX) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.
Lexicon Pharmaceuticals presently has a consensus target price of $3.67, suggesting a potential upside of 233.33%. Sangamo Therapeutics has a consensus target price of $4.50, suggesting a potential upside of 668.44%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Lexicon Pharmaceuticals.
In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Lexicon Pharmaceuticals and 2 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 1.08 beat Lexicon Pharmaceuticals' score of 0.76 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.
Lexicon Pharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.
Sangamo Therapeutics has a net margin of -124.61% compared to Lexicon Pharmaceuticals' net margin of -568.04%. Lexicon Pharmaceuticals' return on equity of -103.16% beat Sangamo Therapeutics' return on equity.
Sangamo Therapeutics has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 13.9% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Sangamo Therapeutics beats Lexicon Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SGMO) was last updated on 7/27/2025 by MarketBeat.com Staff
